Drug intelligence / Profile preview

curcumin + escitalopram

Development stage
Unknown
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Curcumin + escitalopram is a combination of two agents used in the context of depression treatment. Curcumin is a natural polyphenolic compound derived from turmeric (Curcuma longa) with pleiotropic pharmacological properties, including anti-inflammatory, antioxidant, and potential antidepressant effects. Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) approved for major depressive disorder and anxiety disorders. The rationale for combining these agents stems from evidence that curcumin may potentiate the antidepressant effect of SSRIs like escitalopram by modulating neurotransmitter systems (serotonin, dopamine, noradrenaline), neuroprogression pathways, hypothalamic-pituitary-adrenal axis disturbances, inflammation/immune responses, oxidative stress pathways, and mitochondrial function. Clinical studies suggest that while the combination may not significantly outperform standard SSRI therapy in all measures, it could offer more rapid symptom relief without additional adverse effects[1][6]. Drug interaction data indicate that curcumin can decrease the metabolism of escitalopram via CYP450 inhibition[3][4][5], potentially increasing its plasma concentration.

Other names
curcumin + escitalopram
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)SERT (Sodium-dependent serotonin transporter)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on curcumin + escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on curcumin + escitalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call